GLP-1 analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
== TGF-β mimic == The parasitic roundworm Heligmosomoides polygyrus secretes a molecule that mimics the ability of mammalian TGF-β to bind to the TGFβR complex and trigger downstream signalling pathways. This molecule, termed Hp-TGM, shares no sequence homology to TGF-β and is secreted by H. polygyrus in a biologically active form. Hp-TGM consists of 5 domains, with the first three shown to crucial for interaction with the TGFβR complex, with functions for domains 4 and 5 not yet known. Importantly, Hp-TGM shows promise as a novel therapeutic as it induces less fibrosis than TGF-β in vivo in mice and can be used to induce populations of human FOXP3+ regulatory T cells that had much greater stability than those induced by TGF-β.
LGD-4033, also known by the developmental code name VK5211 and by the black-market name Ligandrol, is a selective androgen receptor modulator (SARM) which is under development for the treatment of muscle atrophy in people with hip fracture. It was also under development for the treatment of cachexia, hypogonadism, and osteoporosis, but development for these indications was discontinued. LGD-4033 has been reported to dose-dependently improve lean body mass and muscle strength in preliminary clinical trials, but is still being developed and has not been approved for medical use. The drug is taken by mouth. Known possible side effects of LGD-4033 include headache, dry mouth, adverse lipid changes like decreased high-density lipoprotein (HDL) cholesterol levels, changes in sex hormone concentrations like decreased testosterone levels, elevated liver enzymes, and liver toxicity. The potential of LGD-4033 and other SARMs for producing masculinization is largely uncharacterized and hence is unknown. LGD-4033 is a nonsteroidal SARM, acting as an agonist of the androgen receptor (AR), the biological target of androgens and anabolic steroids like testosterone and dihydrotestosterone (DHT). However, it shows dissociation of effect between tissues in preclinical studies, with agonistic and anabolic effects in muscle and bone and partially agonistic or antagonistic effects in the prostate gland. LGD-4033 was first described in 2010. It is less clinically studied than other SARMs like enobosarm, with only a few small clinical trials having been conducted and reported.
== FSH preparations == Preparations of follicle-stimulating hormone (FSH) mainly include those derived from the urine of menopausal women, as well as recombinant preparations. The recombinant preparations are more pure and more easily administered, but they are more expensive. The urinary preparations are equally effective and less expensive, but are not as convenient to administer as they are available in vials versus injection pens. One study reported that users of the purified urinary FSH preparation Bravelle experienced less injection site pain compared to the recombinant preparation Follistim.
Sources: en.wikipedia.org
Matter is composed of atoms and what makes up atoms. Matter has intrinsic or rest mass. In the limited range of recognized experience of the nineteenth century, it was found that such rest mass is conserved. Einstein's 1905 theory of special relativity showed that rest mass corresponds to an equivalent amount of rest energy. This means that rest mass can be converted to or from equivalent amounts of (non-material) forms of energy, for example, kinetic energy, potential energy, and electromagnetic radiant energy. When this happens, as recognized in twentieth-century experience, rest mass is not conserved, unlike the total mass or total energy. All forms of energy contribute to the total mass and total energy. For example, an electron and a positron each have rest mass. They can perish together, converting their combined rest energy into photons which have electromagnetic radiant energy but no rest mass. If this occurs within an isolated system that does not release the photons or their energy into the external surroundings, then neither the total mass nor the total energy of the system will change. The produced electromagnetic radiant energy contributes just as much to the inertia (and to any weight) of the system as did the rest mass of the electron and positron before their demise. Likewise, non-material forms of energy can perish into matter, which has rest mass. Thus, conservation of energy (total, including material or rest energy) and conservation of mass (total, not just rest) are one (equivalent) law.
The specific adaptive immune response regulated by the TH cell depends on its subtype (i.e., T-helper1, T-helper2, T-helper17, and regulatory T-cell), which is distinguished by the types of cytokines they secrete. Regulatory T cells are yet another distinct population of T cells that provide the critical mechanism of tolerance, whereby immune cells are able to distinguish invading cells from "self." This prevents immune cells from inappropriately reacting against one's own cells, known as an autoimmune response. For this reason, these regulatory T cells have also been called "suppressor" T cells. These same regulatory T cells can also be co-opted by cancer cells to prevent the recognition of, and an immune response against, tumor cells.
According to the National Drug Intelligence Center, Mexican cartels are the predominant smugglers and wholesale distributors of South American cocaine and Mexico-produced cannabis, methamphetamine, and heroin. The U.S. State Department estimates that 90 percent of cocaine entering the United States is produced in Colombia, followed by Bolivia and Peru, and that the main transit route is through Mexico. Mexican cartels control large swaths of territory, and most of the illegal drugs coming into the U.S., employing land routes, maritime shipments, smuggling tunnels, and other concealment methods. Cartels have waged violent turf battles over control of key smuggling corridors from Matamoros to Tijuana. Cartels operate clandestine laboratories that process precursor chemicals into synthetic drugs. These chemicals are primarily imported from Asia, especially China and India, and are used to manufacture methamphetamine and fentanyl in large quantities. Since the 2010s, fentanyl has become one of the most profitable components of cartel operations due to its low production cost and high potency. Although Mexico accounts for only a small share of worldwide heroin production, it supplies a large share of the heroin distributed in the United States. Since the 2000s, Mexican cartels have profited from marijuana cultivation in remote U.S. forests. A 2018 study found that the reduction in drugs from Colombia contributed to Mexican drug violence.
== Applications == Currently, it is used industrially to verify, with a high throughput, the concentrations of brominated flame retardants (BFR) in plastics in compliance with the European Union's RoHS (Restriction of Hazardous Substances) regulation in place since 2006. The banned molecules include PBB and PBDE, whose concentration should not exceed 0.1% w/w. IAMS has also been used to analyze diesel exhaust particles, in ceramic processing, and in critical silicon etching during semiconductor manufacturing.
Sources: en.wikipedia.org
8 June Observation of the axial Higgs mode, a Higgs boson-like excitation in a charge density wave material, is reported. It was incorrectly reported in some press releases as a dark matter particle. Scientists provide an overview of the capabilities of missions and observatories for detecting various alien technosignatures. 9 June A study estimates the air pollution impacts on climate change and the ozone layer from rocket launches and re-entry of reusable components and debris in 2019 and from a theoretical future space industry extrapolated from the "billionaire space race". It concludes that substantial effects from routine space tourism should "motivate regulation". Researchers report a robotic finger covered in a type of manufactured living human skin. Researchers demonstrate an electronic skin giving biological skin-like haptic sensations and touch/pain-sensitivity to a robotic hand (1 June). A system of an electronic skin and a human-machine interface is reported that can enable remote sensed tactile perception, and wearable or robotic sensing of many hazardous substances and pathogens (1 June). A multilayer tactile sensor hydrogel-based robot skin is demonstrated (8 June). 10 June – The core of the globular cluster NGC 3201 is shown to harbor a sub-cluster of nearly a hundred black holes. The same study also confirms that the globular cluster NGC 6397 has ejected most of its original black hole population, and its inner mass excess is composed by hundreds of massive white dwarfs.
1292–1319: Dame Péronelle, French herbalist. 13th century Shen Yu Hsiu, Chinese chemist. fl. 1300 Gilette de Narbonne, French physician. Giovanni Boccaccio wrote of her in ‘’The Decameron’’, calling her ‘Donna Medica’; Alfred Duru and Henri Chivot wrote a comic opera about her called Gillette de Narbonne. f. 1307 Trotta da Toya, Napolitan physician. fl. 1308 Francisca di Vestis, Napolian physician. fl. 1309 Maria Gallicia, licensed surgeon. fl. 1313–1325: Ameline la Miresse, French physician. fl. 1318–1324: Adelmota of Carrara was a physician in Padua, Italy. fl. 1318: Alessandra Giliani, Italian anatomist. 1320: Raymunda da Taberna, licensed Napolitan surgeon. fl. 1322: Fava of Manosque, French-Jewish physician. fl. 1322: Jacobina Félicie, Italian physician. fl. 1326: Sara de Sancto Aegidio, French physician. fl. 1326: Sarah de St Giles, French-Jewish physician and medical teacher. fl. 1333: Constanza, Italian surgeon, mentioned in Pope Sixtus IV edict regarding physicians and surgeons. fl. 1333: Francisca da Romana, Napolitan physician. fl. 1333: Isabella da Ocre, Napolitan surgeon. fl. 1333: Lauretta Ponte da Saracena Calabria, Napolitan physician. fl. 1333: Margarita da Venosa, licensed Napolitan surgeon, who studied at the University of Salerno She was considered a noteworthy practitioner and counted Ladislaus, king of Naples, as a patient. fl. 1333: Maria Incarnata, Italian surgeon, mentioned in Pope Sixtus IV edict regarding physicians and surgeons. fl. 1333: Sibyl of Benevento, Napolitan physician specializing in the plague buboes fl.
==== French Polynesia ==== In French Polynesia, glass noodles are known as vermicelle de soja and were introduced to the islands by Hakka agricultural workers during the 19th century. They are most often used in maʻa tinito, a dish made with glass noodles mixed together with pork, beans, and cooked vegetables.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.